PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
EDIT vs. CRSP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

EDIT vs. CRSP

Last updated May 16, 2025

Compare and contrast key facts about Editas Medicine, Inc. (EDIT) and CRISPR Therapeutics AG (CRSP).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EDIT or CRSP.

Correlation

The correlation between EDIT and CRSP is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Performance

EDIT vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

EDIT:

-0.60

CRSP:

-0.65

Sortino Ratio

EDIT:

-0.98

CRSP:

-0.75

Omega Ratio

EDIT:

0.89

CRSP:

0.92

Calmar Ratio

EDIT:

-0.76

CRSP:

-0.41

Martin Ratio

EDIT:

-1.32

CRSP:

-1.16

Ulcer Index

EDIT:

57.24%

CRSP:

29.92%

Daily Std Dev

EDIT:

127.82%

CRSP:

55.73%

Max Drawdown

EDIT:

-98.92%

CRSP:

-85.11%

Current Drawdown

EDIT:

-98.46%

CRSP:

-82.71%

Fundamentals

Market Cap

EDIT:

$115.52M

CRSP:

$3.07B

EPS

EDIT:

-$3.04

CRSP:

-$4.49

PEG Ratio

EDIT:

0.00

CRSP:

-0.21

PS Ratio

EDIT:

3.22

CRSP:

81.61

PB Ratio

EDIT:

1.85

CRSP:

1.68

Total Revenue (TTM)

EDIT:

$35.84M

CRSP:

$36.12M

Gross Profit (TTM)

EDIT:

$26.78M

CRSP:

-$93.67M

EBITDA (TTM)

EDIT:

-$175.04M

CRSP:

-$455.24M

Returns By Period

In the year-to-date period, EDIT achieves a 9.84% return, which is significantly higher than CRSP's -7.75% return.

EDIT

YTD

9.84%

1M

3.33%

6M

-49.64%

1Y

-76.75%

5Y*

-44.51%

10Y*

N/A

CRSP

YTD

-7.75%

1M

-6.78%

6M

-22.50%

1Y

-36.25%

5Y*

-9.91%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Risk-Adjusted Performance

EDIT vs. CRSP — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
EDIT
The Risk-Adjusted Performance Rank of EDIT is 1212
Overall Rank
The Sharpe Ratio Rank of EDIT is 1818
Sharpe Ratio Rank
The Sortino Ratio Rank of EDIT is 1212
Sortino Ratio Rank
The Omega Ratio Rank of EDIT is 1414
Omega Ratio Rank
The Calmar Ratio Rank of EDIT is 66
Calmar Ratio Rank
The Martin Ratio Rank of EDIT is 1212
Martin Ratio Rank
CRSP
The Risk-Adjusted Performance Rank of CRSP is 1919
Overall Rank
The Sharpe Ratio Rank of CRSP is 1515
Sharpe Ratio Rank
The Sortino Ratio Rank of CRSP is 1717
Sortino Ratio Rank
The Omega Ratio Rank of CRSP is 1919
Omega Ratio Rank
The Calmar Ratio Rank of CRSP is 2424
Calmar Ratio Rank
The Martin Ratio Rank of CRSP is 1919
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EDIT vs. CRSP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current EDIT Sharpe Ratio is -0.60, which is comparable to the CRSP Sharpe Ratio of -0.65. The chart below compares the historical Sharpe Ratios of EDIT and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading data...

Dividends

EDIT vs. CRSP - Dividend Comparison

Neither EDIT nor CRSP has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

EDIT vs. CRSP - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.92%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for EDIT and CRSP. For additional features, visit the drawdowns tool.

Loading data...

Volatility

EDIT vs. CRSP - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 28.91% compared to CRISPR Therapeutics AG (CRSP) at 18.02%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading data...

Financials

EDIT vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Editas Medicine, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

0.00200.00M400.00M600.00M800.00M1.00B20212022202320242025
4.66M
0
(EDIT) Total Revenue
(CRSP) Total Revenue
Values in USD except per share items